Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03052127 · ClinicalTrials.gov registry record · Phase 1
Study in Subjects With Small Primary Choroidal Melanoma
A Phase 1 study, sponsored by Aura Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT03052127 is a Phase 1 study that has completed, run by Aura Biosciences. The registered enrollment target is 57 participants.
The verdict
NCT03052127, a Phase 1 study, has completed, sponsored by Aura Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
Interventions
- DRUG Light-activated AU-011
- DEVICE Laser Activation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2021-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03052127
The ClinicalTrials.gov registry entry for NCT03052127 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aura Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Light-activated AU-011 is the first listed.
NCT03052127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03052127 about?
NCT03052127 is a clinical study titled "Study in Subjects With Small Primary Choroidal Melanoma". The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
What is the current status of trial NCT03052127?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2017-02-27. Estimated completion is 2021-01-26.
What interventions are being tested in trial NCT03052127?
The interventions under investigation include: Light-activated AU-011 (DRUG), Laser Activation (DEVICE).
Who is sponsoring clinical trial NCT03052127?
This trial is sponsored by Aura Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.